

GLAXOSMITHKLINE PLC
Form 6-K
August 01, 2008

FORM 6-K

**SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549**

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For period ending August 01, 2008

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

**GlaxoSmithKline plc received on 31 July 2008 from Legal & General Group plc a notification of interests in
GlaxoSmithKline plc Ordinary shares of 25 pence each , dated 31 July 2008 . This notice is given in**

accordance with DTR 5.8.12.

TR-1: notification of major interests in shares

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

GlaxoSmithKline Plc

2. Reason for notification (yes/no)

An acquisition or disposal of voting rights

Yes

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An event changing the breakdown of voting rights

Other (please specify): _____

3. Full name of person(s) subject to the notification obligation:

Legal & General Group Plc (Group)

Legal & General Investment Management Limited (LGIM)

4. Full name of shareholder(s) (if different from 3.):

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Group Plc (L&G)

30 July 2008

5. Date of the transaction (and date on which the threshold is crossed or reached if different):

6. Date on which issuer notified:

31 July 2008

7. Threshold(s) that is/are crossed or reached:

Below 5% (Group)

Below 5% (LGIM)

8. Notified details:

A: Voting rights attached to shares

Class/type Situation previous to the triggering transaction
Resulting situation after the triggering transaction

if possible using the ISIN CODE	Number of Shares	Number of Voting Rights	Number of shares		Number of voting rights		% of voting rights	
			Direct	Indirect	Direct	Indirect		
ORD GBP0.25	283,832,153	283,832,153					Below 5%	

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument	Expiration date	Exercise/ Conversion Period/ Date	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights

Total (A+B)

Number of voting rights

% of voting rights
Below 5%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

Legal & General Group Plc (Direct and Indirect) (Group) (
Below 5%)

Legal & General Investment Management (Holdings) Limited
(LGIMH) (Direct and Indirect) (Below 5%)

Legal & General Investment Management Limited (Indirect)
(LGIM) (Below 5%)

Legal & General Group Plc (Direct) (L&G) (244,009,760 –4.65 % = LGAS, LGPL &
PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD) (200,360,654 –3.82
% = PMC) Legal & General Insurance Holdings Limited (Direct) (LGIH)

Legal & General Assurance (Pensions Management) Limited (PMC) (200,360,654 –3.82 % = PMC) Legal & General Assurance Society Limited (LGAS & LGPL)

Legal & General Pensions Limited (Direct)
(LGPL)

Proxy Voting:

10. Name of the proxy holder: N/A

11. Number of voting rights proxy holder will cease to hold: N/A

12. Date on which proxy holder will cease to hold voting rights: N/A

13. Additional information:

Notification using the total voting rights figure of
5,240,433,283

14. Contact name:

Helen Lewis (LGIM)

15. Contact telephone number:

020 3124 3851

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: August 01, 2008

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc